Accustem Sciences reported revenue of $0.10M and net income of -$0.25M for the quarter ended Jun 2026. This income statement covers 22 quarters of results from Mar 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||
| Revenue | 0.10M | |||||||||||||||||||||
| Operating items | ||||||||||||||||||||||
| Research & DevelopmentR&D | 0.01M | 0.03M | 0.02M | 0.05M | 0.06M | 0.13M | 0.02M | 0.01M | 0.02M | 0.09M | 0.02M | 0.04M | 0.03M | 0.04M | 0.03M | 0.06M | 0.07M | 0.12M | 0.12M | 0.04M | ||
| Selling, General & AdministrativeSG&A | 0.05M | 0.52M | 0.77M | 1.02M | 0.84M | 0.85M | 0.82M | 0.36M | 0.58M | 0.16M | 0.50M | 0.24M | 0.30M | 0.33M | 0.41M | 0.34M | 0.33M | 0.39M | 0.37M | 0.31M | ||
| Operating ExpensesOpex | 0.06M | 0.54M | 0.79M | 1.08M | 0.90M | 0.98M | 0.83M | 0.37M | 0.60M | 0.25M | 0.53M | 0.28M | 0.33M | 0.37M | 0.44M | 0.40M | 0.40M | 0.51M | 0.49M | 0.35M | ||
| Operating IncomeOp. Inc | -0.06M | -0.54M | -0.79M | -1.08M | -0.90M | -0.98M | -0.83M | -0.37M | -0.60M | -0.25M | -0.53M | -0.28M | -0.33M | -0.37M | -0.44M | -0.40M | -0.40M | -0.51M | -0.49M | -0.25M | ||
| EBIT | -0.06M | -0.54M | -0.79M | -1.08M | -0.90M | -0.98M | -0.83M | -0.37M | -0.60M | -0.25M | -0.53M | -0.28M | -0.33M | -0.37M | -0.44M | -0.40M | -0.40M | -0.51M | -0.49M | -0.25M | ||
| Net income details | ||||||||||||||||||||||
| EBT | -0.06M | -0.54M | -0.79M | -1.08M | -0.90M | -0.98M | -0.83M | -0.37M | -0.60M | -0.25M | -0.53M | -0.28M | -0.33M | -0.37M | -0.44M | -0.40M | -0.40M | -0.51M | -0.49M | -0.25M | ||
| Profit After TaxPAT | -0.06M | -0.54M | -0.79M | -1.08M | -0.90M | -0.98M | -0.83M | -0.37M | -0.60M | -0.25M | -0.53M | -0.28M | -0.33M | -0.37M | -0.44M | -0.40M | -0.40M | -0.51M | -0.49M | -0.25M | ||
| Income from Continuing OperationsIncome (Continuing) | -0.06M | -0.54M | -0.79M | -1.08M | -0.90M | -0.98M | -0.83M | -0.37M | -0.60M | -0.25M | -0.53M | -0.28M | -0.33M | -0.37M | -0.44M | -0.40M | -0.40M | -0.51M | -0.49M | -0.25M | ||
| Consolidated Net IncomeConsol Net Inc. | -0.06M | -0.54M | -0.79M | -1.08M | -0.90M | -0.98M | -0.83M | -0.37M | -0.60M | -0.25M | -0.53M | -0.28M | -0.33M | -0.37M | -0.44M | -0.40M | -0.40M | -0.51M | -0.49M | -0.25M | ||
| Income towards Parent CompanyParent Net Inc | -0.06M | -0.54M | -0.79M | -1.08M | -0.90M | -0.98M | -0.83M | -0.37M | -0.60M | -0.25M | -0.53M | -0.28M | -0.33M | -0.37M | -0.44M | -0.40M | -0.40M | -0.51M | -0.49M | -0.25M | ||
| Net Income towards Common StockholdersNet Income | -0.06M | -0.54M | -0.79M | -1.08M | -0.90M | -0.98M | -0.83M | -0.37M | -0.60M | -0.25M | -0.53M | -0.28M | -0.33M | -0.37M | -0.44M | -0.40M | -0.40M | -0.51M | -0.49M | -0.25M | ||
| Additional items | ||||||||||||||||||||||
| EPS (Basic) | -0.01 | -0.05 | -0.08 | -0.10 | -0.08 | -0.09 | -0.07 | -0.03 | -0.05 | -0.02 | -0.05 | -0.02 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.03 | -0.02 | ||
| EPS (Diluted) | -0.10 | -0.08 | -0.09 | -0.07 | -0.03 | -0.05 | -0.02 | -0.05 | -0.02 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.03 | -0.02 | |||||
| Shares Outstanding | 10.00M | 10.00M | 10.03M | 11.34M | 11.34M | 11.02M | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M | 11.44M | 12.72M | 16.07M | 16.07M | 15.23M | 16.07M | 16.07M | ||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 11.34M | 11.34M | 11.02M | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M | 11.44M | 12.72M | 16.07M | 16.07M | 15.23M | 16.07M | 16.07M | |||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 10.00M | 10.00M | 11.34M | 11.34M | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M | 12.10M | 12.72M | 16.07M | 16.07M | 16.07M | 16.07M | 16.07M | ||
| EBITDA | -0.06M | -0.79M | -1.08M | -0.90M | -0.98M | -0.83M | -0.37M | -0.60M | -0.25M | -0.53M | -0.28M | -0.33M | -0.37M | -0.44M | -0.40M | -0.40M | -0.51M |
Pull Accustem Sciences's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=ACUT&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "ACUT", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=ACUT&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();